Cargando…

Challenges on off label medicine use

Detalles Bibliográficos
Autor principal:	Carvalho, Marisa Lima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade de Pediatria de São Paulo 2016
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795713/ https://www.ncbi.nlm.nih.gov/pubmed/26589901 http://dx.doi.org/10.1016/j.rppede.2015.12.007

Ejemplares similares

Off-label use of medicines: Medical research and medical practice
por: Khamar, Bakulesh
Publicado: (2007)

When is off-label off-road?
por: de Vries, E G E, et al.
Publicado: (2019)

Gabapentin May Be Appropriate for Off-Label Uses
por: Davis, Shawn
Publicado: (2003)

Off-label use of drugs: An evil or a necessity?
por: Gota, Vikram, et al.
Publicado: (2015)

Use of off-label and unlicensed medicines in neonatal intensive care
por: Costa, Haline Tereza Matias de Lima, et al.
Publicado: (2018)

Off-label Medication Use: A Double-edged Sword
por: Agarwal, Vandana
Publicado: (2021)

Use of Drugs for Off-Label Indications: Living in the Same World
por: Barbuto, John P.
Publicado: (2003)

Understanding off-label use and the new challenges
por: Dooms, Marc
Publicado: (2014)

Pulmonary Artery Stents-Still "Off Label"
por: Kim, Seong-Ho
Publicado: (2012)

A tale of two drugs: Off and on-label
por: Narayanan, Raja, et al.
Publicado: (2017)

Parents’ awareness and perspective on off-label medicines use in children
por: Saiyed, Mohd Masnoon, et al.
Publicado: (2015)

Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide(®))
por: Tjon Pian Gi, Robin E. A., et al.
Publicado: (2011)

Regulatory Actions on the Off-Label Use of Prescription Drugs: Ongoing Controversy and Contradiction in 2009 and 2010
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Off-label indications for bioresorbable scaffolds: “Beethoven can, but you cannot”
por: Gutiérrez-Chico, Juan Luis, et al.
Publicado: (2016)

Contradictory Actions on Off-Label Use of Prescription Drugs? The FDA and CMS Versus the U.S. Justice Department
por: Curtiss, Frederic R.
Publicado: (2009)

Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics
por: Lenk, Christian, et al.
Publicado: (2009)

Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use—Patient Harms and Prescriber Responsibilities
por: Van Norman, Gail A.
Publicado: (2023)

Off‐label and unlicensed medicines to hospitalised children in Norway
por: Teigen, Arna, et al.
Publicado: (2016)

Safety and Efficacy of Off-label and Unlicensed Medicines in Children
por: Lee, Ji-Hyun, et al.
Publicado: (2018)

Assessment of novel technologies in healthcare - off-label use of drugs and the ethics of implementation and distribution of COVID-19 vaccines
por: Avelino-Silva, Vivian Iida, et al.
Publicado: (2021)

Rational use of medicines: Achievements and challenges
por: Thawani, Vijay
Publicado: (2010)

Peeling off musculoskeletal labels: sticks and stones may break my bones, but diagnostic labels can hamstring me forever
por: Friedman, Daniel Jonah, et al.
Publicado: (2021)

Off with the label and on the Avastin bandwagon: Why now and how far?
por: Gopal, K. S. Santhan
Publicado: (2009)

Videolaryngoscopy in anesthesia and perioperative medicine: innovations, challenges, and best practices
por: Quintão, Vinícius Caldeira, et al.
Publicado: (2023)

The next forum for unraveling FDA off-label marketing rules: State and federal legislatures
por: Sinha, Michael S., et al.
Publicado: (2018)

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs
por: Overbeek, J.K., et al.
Publicado: (2023)

Outbreaks of iatrogenic botulism in Europe: Combating off-label medical use of Botulinum Neurotoxin (BoNT) in bariatric procedures
por: Jain, Nityanand, et al.
Publicado: (2023)

Off-label use of orphan medicinal products: a Belgian qualitative study
por: Dooms, Marc, et al.
Publicado: (2016)

COVID-19 off-label uses of medicines: the role of civil liability and regulation
por: Parziale, Andrea
Publicado: (2023)

Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations
por: Belayneh, Anteneh, et al.
Publicado: (2020)

A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic
por: Bassetti, Matteo, et al.
Publicado: (2020)

The extent to which off-patent registered prescription medicines are used for off-label indications in Australia: A scoping review
por: Howe, Katrina, et al.
Publicado: (2021)

When is off-label off-road?
por: de Vries, E G E, et al.
Publicado: (2019)

Treating Cancers Using Nature’s Medicine: Significance and Challenges
por: Samuel, Samson Mathews, et al.
Publicado: (2021)

Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities
por: Gupta, Sandeep Kumar, et al.
Publicado: (2014)

Tranexamsäure und Endoprothetik: zwischen „off label use“ und „evidence-based medicine“
por: Lier, Heiko, et al.
Publicado: (2021)

Bevacizumab: Off-label use in ophthalmology
por: Grisanti, Salvatore, et al.
Publicado: (2007)

Methylphenidate off-label use and safety
por: Trenque, Thierry, et al.
Publicado: (2014)

Off-label use of misoprostol in gynaecology
por: Turner, JV, et al.
Publicado: (2015)

„Off-label use“ in der Herzchirurgie
por: Fenger, H., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tg5mkedn5lfrr21nkpaducbomi